Mineral and bone disorders (MBD) are among the common complications afflicting patients who have undergone renal transplantation. MBD typically manifests as loss of bone volume and the presence of mineralization problems. Routine application of adequate diagnostic tools as well as treatment to prevent further bone loss often is insufficient. Despite insufficient data to suggest any bone-specific therapies during the first-year post-transplant, some potential treatment options are available.
This activity has been designed to meet the education need of nephrologists and other clinicians involved in the care of renal transplant recipients.
After completing the activity, the participant should be better able to:
- Explain the major factors that contribute to MBD, including the effects of transplantation-related treatment.
- Review appropriate therapeutic options to manage bone loss after renal transplantation.
Statement of Need:
Bone disease is a well-known complication in kidney transplant recipients, who experience a raid loss of bone mass, especially during the early post-transplant period. The management of this bone loss often is insufficient and nephrologists and other clinicians involved in the care of renal transplant recipients need to understand mineral bone disease (MBD) in these patients and be aware of the various treatment options available to prevent bone loss.
AMA PRA Category 1 Credit(s)TM
This activity has been planned and implemented in accordance with the Essential Areas and Policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint sponsorship of Medical Education Resources (MER) and Haymarket Media, Inc. MER is accredited by the ACCME to provide continuing medical education for physicians.
Medical Education Resources designates this enduring material for a maximum of 1.00 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Miklos Z. Molnar, MD, PhD
Harold Simmons Center for Chronic Disease Research and Epidemiology
Los Angeles Biomedical Research Institute
Harbor-UCLA Medical Centre
Kamyar Kalantar-Zadeh, MD, MPH, PhD
Professor of Medicine, Pediatrics and Epidemiology
UCLA David Geffen School of Medicine/UCLA School of Public Health
Director of the Harold Simmons Center
for Chronic Disease Research and Epidemiology
Disclosure of Conflicts of Interest
Medical Education Resources insures balance, independence, objectivity, and scientific rigor in all our educational programs. In accordance with this policy, MER identifies conflicts of interest with its instructors, content managers, and other individuals who are in a position to control the content of an activity. Conflicts are resolved by MER to ensure all scientific research referred to, reported, or used in a CME activity conforms to the generally accepted standards of experimental design, data collection, and analysis. MER is committed to providing its learners with high-quality CME activities that promote improvements or quality in health care and not the business interest of a commercial interest.
Miklos Z. Molnar, MD, PhD
No financial relationships to disclose
Kamyar Kalantar-Zadeh, MD, MPH, PhD
Grants/Research Support: NIH, NKF, Abbott, Shire
Consultant: NIH, Abbott, Amgen, DaVita, Fresenius-Kabi, Genzyme, Otsuka, Shire, Vifor
Speakers’ Bureau: Abbott, Amgen, Fresenius-Kabi, Otsuka, Shire
Publishing Staff Disclosures:
The content managers, Jody A. Charnow, and Marina Galanakis of Haymarket Media Inc., and Julie Johnson, PharmD, of Medical Education Resources, have disclosed that they have no relevant financial relationships or conflicts of interest relating directly or indirectly to this activity.
Disclosure of Unlabeled Use:
This educational activity may contain discussion of approved and/or investigational uses of agents that are not indicated by the FDA. Medical Education Resources, Inc. (MER), and Haymarket Medical Education (HME) do not recommend the use of any agent outside of the labeled indications.
The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of MER and HME. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
The content and views presented in this educational activity are those of the authors and do not necessarily reflect those of Medical Education Resources or Haymarket Media, Inc. The authors have disclosed if there is any discussion of published and/or investigational uses of agents that are not indicated by the FDA in their presentations. The opinions expressed in this educational activity are those of the faculty and do not necessarily represent the views of Medical Education Resources, or Haymarket Media, Inc. Before prescribing any medicine, primary references and full prescribing information should be consulted. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications on dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities. The information presented in this activity is not meant to serve as a guideline for patient management.
This activity is jointly sponsored by Medical Education Resources and Haymarket Media.
If you have any questions relating to the accreditation of this activity, please contact:
Medical Education Resources, Inc.
1500 West Canal Court
Littleton, CO 80120-5615
To obtain credit, a post-test score of 70% or better is required. This CME is offered at no cost to participants. Please proceed with the activity until you have successfully completed this program, answered all test questions, completed the post-test survey, and have received a digital copy of your credit certificate. Your online certificate will be saved on myCME.com within your Profile/Exam History, which you can then access at any time.
WINDOWS PC SYSTEM REQUIREMENTS:
266-MHz Pentium II; Windows 98 or higher; 64 MB RAM; 800 x 600 screen resolution
set for “High Color (16-Bit)”; Macromedia Flash Player 6 or higher.
MACINTOSH® SYSTEM REQUIREMENTS:
Power Mac g3 at 300 MHz; System 8.5 or higher (excluding Mac OSX); 96 MB RAM; 20
MB minimum hard disk space available; 800 x 600 screen resolution set to “Thousands
of Colors”; Macromedia Flash Player 6 or higher.